Background
Methods
Study populations
Diagnosis and classification of VTE
Laboratory methods
Statistical methods
Results
Patient characteristics
Characteristic | All patients | Patients with VTE |
---|---|---|
(n = 605) (%) | (n = 71) (%) | |
Median age, years | 62 | 60 |
25th–75th percentile | 55–69 | 51–69 |
< 60 | 237 (39.2) | 32 (45.1) |
≥ 60 | 368 (60.8) | 39 (54.9) |
Sex | ||
Male | 352 (58.2) | 40 (56.3) |
Female | 253 (41.8) | 31 (43.7) |
ECGO PS | ||
0–1 | 424 (70.1) | 41 (57.7) |
2–3 | 181 (29.9) | 30 (42.3) |
Tumor histology | ||
Adenocarcinoma | 471 (77.9) | 62 (87.3) |
Non-adenocarcinoma | 134 (22.1) | 9 (12.7) |
Squamous cell carcinoma | 125 (20.7) | 8 (11.3) |
Other NSCLC | 9 (1.4) | 1 (1.4) |
Tumor Stage | ||
Localized | 137 (22.6) | 16 (22.5) |
Distant metastasis | 468 (77.4) | 55 (77.5) |
EGFR gene | ||
Wild | 361 (59.7) | 49 (69.0) |
Mutated | 244 (40.3) | 22 (31.0) |
KRAS gene | ||
Wild | 543 (89.8) | 61 (85.9) |
Mutated | 62 (10.2) | 10 (14.1) |
Treatment during observation period | ||
Other treatment without TKI | 220 (36.4) | 27 (38.0) |
Other treatment with TKI | 96 (15.9) | 13 (18.3) |
TKI alone | 141 (23.3) | 11 (15.5) |
Chemotherapy alone | 148 (24.5) | 20 (28.2) |
Development of VTE
Type/Site of VTE | No. of patients (%) |
---|---|
Total episodes | 71 (11.7) |
DVT alone | 44 (7.3) |
Upper extremity and neck | 10 (1.6) |
Lower extremity and pelvis | 32 (5.3) |
Upper extremity and lower extremity | 2 (0.3) |
PE alone | 7 (1.1) |
Segmental/subsegmental | 4 (0.6) |
Above segmental | 3 (0.5) |
DVT and PE combined | 20 (3.3) |
Lower extremity, pelvis DVT and segmental PE | 13 (2.1) |
Upper extremity, pelvis DVT and above segmental PE | 1 (0.2) |
Lower extremity, pelvis DVT and above segmental PE | 4 (0.6) |
Upper extremity, lower extremity DVT and segmental PE | 2 (0.3) |
Mutations and risk of VTE
Mutation type | Number | VTE |
---|---|---|
(n = 306) (%) | (n = 32) (%) | |
EGFR exon 18 mutation only | 3 (1.0) | 0 (0.0) |
EGFR exon 19 deletion only | 106 (34.6) | 9 (28.1) |
EGFR exon 20 T790 M only | 0 (0.0) | 0 (0.0) |
EGFR exon 20 S768I only | 4 (1.3) | 0 (0.0) |
EGFR exon 20 insertion only | 11 (3.6) | 0 (0.0) |
EGFR exon 21 L858R only | 106 (34.6) | 12 (37.5) |
EGFR exon 21 L861Q only | 7 (2.3) | 0 (0.0) |
EGFR exon 18 + exon 21 L861Q | 1 (0.3) | 0 (0.0) |
EGFR exon 18 + exon 20 S768I | 2 (0.6) | 1 (3.1) |
EGFR exon 19 + exon 21 L861Q | 1 (0.3) | 0 (0.0) |
EGFR exon 19 + exon 20 T790 M | 1 (0.3) | 0 (0.0) |
EGFR exon 20 T790 M + exon 21 L858R | 1 (0.3) | 0 (0.0) |
EGFR exon 20 S768I + exon 21 L858R | 1 (0.3) | 0 (0.0) |
KRAS codon G12C(34G > T) only | 19 (6.2) | 5 (15.6) |
KRAS codon G12S(34G > A) only | 2 (0.6) | 2 (6.3) |
KRAS codon G12R(34G > C) only | 5 (1.6) | 0 (0.0) |
KRAS codon G12 V(35G > T) only | 14 (4.6) | 3 (9.4) |
KRAS codon G12D(35G > A) only | 12 (3.9) | 0 (0.0) |
KRAS codon G12A(35G > C) only | 9 (2.9) | 0 (0.0) |
KRAS codon G13D(38G > A) only | 0 (0.0) | 0 (0.0) |
KRAS codon G12R(34G > C) + codon G12D(35G > A) | 1 (0.3) | 0 (0.0) |
Patients Group | SHR | 95% CI |
P-value
|
---|---|---|---|
Tumor histology (%) | |||
Non-adenocarcinoma | 1 | ||
Adenocarcinoma | 2.40 | 1.11–5.19 | 0.027 |
ECOG PS | |||
0–1 | 1 | ||
2–3 | 1.91 | 1.18–3.09 | 0.008 |
EGFR gene | |||
Mutated | 1 | ||
Wild | 1.81 | 1.07–3.07 | 0.028 |
Age | |||
≥ 60 | 1 | ||
< 60 | 1.27 | 0.79–2.02 | 0.324 |
Sex | |||
Female | 1 | ||
Male | 1.03 | 0.63–1.66 | 0.920 |
Tumor Stage | |||
Distant metastasis | 1 | ||
Localized | 1.18 | 0.67–2.07 | 0.569 |
KRAS gene | |||
Wild | 1 | ||
Mutated | 1.10 | 0.52–2.32 | 0.814 |